📊 ADMA Key Takeaways
Is Adma Biologics, Inc.. (ADMA) a Good Investment?
ADMA Biologics demonstrates solid fundamental strength with robust revenue growth of 19.6% YoY, exceptional profitability metrics (57.4% gross margin, 28.8% net margin), and a fortress balance sheet with minimal leverage. However, net income declined 25.7% YoY despite revenue growth, signaling profitability headwinds that warrant monitoring despite strong operational efficiency.
ADMA Biologics shows strong underlying fundamentals with nearly 20% revenue growth, very high gross and operating margins, and a conservatively levered balance sheet. Financial health is robust given high liquidity, low debt, and strong interest coverage, but the decline in net income and modest free cash flow conversion suggest growth quality should be monitored closely. Overall, the business appears fundamentally strong, with some caution warranted around earnings durability and cash generation.
Why Buy Adma Biologics, Inc.. Stock? ADMA Key Strengths
- Revenue growth of 19.6% YoY with $510.2M in sales demonstrates healthy market demand
- Exceptional profitability with 57.4% gross margin and 28.8% net margin, indicating pricing power and operational efficiency
- Strong balance sheet with $477.3M equity, 6.71x current ratio, and minimal 0.15x debt/equity leverage
- Robust free cash flow generation of $27.8M with 50.8x interest coverage providing financial flexibility
- High return metrics (30.8% ROE, 23.5% ROA) demonstrate efficient capital deployment
- Strong profitability profile with 57.4% gross margin, 37.5% operating margin, and 28.8% net margin
- Excellent balance sheet quality with 6.71x current ratio, 0.15x debt-to-equity, and 50.8x interest coverage
- Solid top-line growth of 19.6% YoY supported by strong returns on capital, including 30.8% ROE and 23.5% ROA
ADMA Stock Risks: Adma Biologics, Inc.. Investment Risks
- Net income declined 25.7% YoY despite 19.6% revenue growth, indicating margin compression or operational cost increases
- Low free cash flow margin of 5.5% relative to net income suggests working capital or capex pressures
- Capital expenditures of $22.6M represent 44% of operating cash flow, reducing distributable cash
- Operating leverage concerns given revenue growth not translating to earnings growth
- High insider activity with 18 Form 4 filings in last 90 days may signal management uncertainty
- Net income and diluted EPS declined about 26% YoY despite revenue growth, which may indicate normalization, higher costs, or non-operating pressure
- Free cash flow remains relatively modest at $27.82M, with only a 5.5% FCF margin versus much higher accounting profitability
- As a biologics manufacturer, sustaining current margins may depend on continued production efficiency, plasma economics, and product mix
Key Metrics to Watch
- Operating expense trends to explain net income decline despite revenue growth
- Gross margin sustainability and pricing power maintenance
- Free cash flow conversion and working capital management efficiency
- Capital expenditure requirements and return on invested capital
- Revenue composition and customer concentration risk
- Free cash flow conversion relative to net income
- Net margin and operating margin sustainability
Adma Biologics, Inc.. (ADMA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.71x current ratio provides a solid financial cushion.
ADMA Profit Margin, ROE & Profitability Analysis
ADMA vs Healthcare Sector: How Adma Biologics, Inc.. Compares
How Adma Biologics, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Adma Biologics, Inc.. Stock Overvalued? ADMA Valuation Analysis 2026
Based on fundamental analysis, Adma Biologics, Inc.. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Adma Biologics, Inc.. Balance Sheet: ADMA Debt, Cash & Liquidity
ADMA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Adma Biologics, Inc..'s revenue has grown significantly by 530% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.13 indicates the company is currently unprofitable.
ADMA Revenue Growth, EPS Growth & YoY Performance
ADMA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $119.8M | $17.8M | $0.15 |
| Q2 2025 | $107.2M | $17.8M | $0.13 |
| Q1 2025 | $81.9M | $17.8M | $0.08 |
| Q3 2024 | $67.3M | $2.6M | $0.01 |
| Q2 2024 | $60.1M | -$6.4M | $-0.03 |
| Q1 2024 | $56.9M | -$6.8M | $-0.03 |
| Q3 2023 | $41.1M | $2.6M | $0.01 |
| Q2 2023 | $33.9M | -$6.4M | $-0.03 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Adma Biologics, Inc.. Dividends, Buybacks & Capital Allocation
ADMA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Adma Biologics, Inc.. (CIK: 0001368514)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ADMA
What is the AI rating for ADMA?
Adma Biologics, Inc.. (ADMA) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (BUY) with 75% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ADMA's key strengths?
Claude: Revenue growth of 19.6% YoY with $510.2M in sales demonstrates healthy market demand. Exceptional profitability with 57.4% gross margin and 28.8% net margin, indicating pricing power and operational efficiency. ChatGPT: Strong profitability profile with 57.4% gross margin, 37.5% operating margin, and 28.8% net margin. Excellent balance sheet quality with 6.71x current ratio, 0.15x debt-to-equity, and 50.8x interest coverage.
What are the risks of investing in ADMA?
Claude: Net income declined 25.7% YoY despite 19.6% revenue growth, indicating margin compression or operational cost increases. Low free cash flow margin of 5.5% relative to net income suggests working capital or capex pressures. ChatGPT: Net income and diluted EPS declined about 26% YoY despite revenue growth, which may indicate normalization, higher costs, or non-operating pressure. Free cash flow remains relatively modest at $27.82M, with only a 5.5% FCF margin versus much higher accounting profitability.
What is ADMA's revenue and growth?
Adma Biologics, Inc.. reported revenue of $510.2M.
Does ADMA pay dividends?
Adma Biologics, Inc.. does not currently pay dividends.
Where can I find ADMA SEC filings?
Official SEC filings for Adma Biologics, Inc.. (CIK: 0001368514) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ADMA's EPS?
Adma Biologics, Inc.. has a diluted EPS of $0.60.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ADMA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Adma Biologics, Inc.. has a BUY rating with 75% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is ADMA stock overvalued or undervalued?
Valuation metrics for ADMA: ROE of 30.8% (sector avg: 15%), net margin of 28.8% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy ADMA stock in 2026?
Our dual AI analysis gives Adma Biologics, Inc.. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is ADMA's free cash flow?
Adma Biologics, Inc..'s operating cash flow is $50.4M, with capital expenditures of $22.6M. FCF margin is 5.5%.
How does ADMA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 28.8% (avg: 12%), ROE 30.8% (avg: 15%), current ratio 6.71 (avg: 2).
Why is ADMA's return on equity (ROE) so high?
Adma Biologics, Inc.. has a return on equity of 30.8%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 28.8% net margin.